Reem Karmali
Northwestern University · Rush Medical Center · Assistant Professor of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Reem Karmali as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06723457 · Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaReem Karmali · recruiting · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT06242834 · Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaNorthwestern University · active not recruiting · B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT05202782 · Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaNorthwestern University · active not recruiting · Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified · principal investigator
- Ph1NCT03742258 · Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaNorthwestern University · completed · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type · principal investigator
- Ph1/Ph2NCT03704714 · Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaNorthwestern University · suspended · Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive · principal investigator
- Ph2NCT02815397 · DA-EPOCH-Rituximab/Metformin (RM) for Double Hit LymphomaRush University Medical Center · terminated · Diffuse Large B-Cell Lymphoma · principal investigator
- Ph2NCT02531308 · Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)Rush University Medical Center · terminated · Diffuse Large B-Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA060553 · NCI · NORTHWESTERN UNIVERSITY · PI Aleksandar Zafirovski · fiscal years 2012 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:21 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- 142 citationsRCR 16.0
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.Blood · 2021121 citationsRCR 6.4
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.Lancet Haematol · 2020117 citationsRCR 4.1
- 73 citationsRCR 5.1
- 63 citationsRCR 4.9
- Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.J Clin Oncol · 201843 citationsRCR 1.6
- Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.Blood Adv · 202334 citationsRCR 3.0
- A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.Leuk Lymphoma · 202124 citationsRCR 1.6
- Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.Clin Cancer Res · 202023 citationsRCR 0.9
- Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.Clin Lymphoma Myeloma Leuk · 201118 citationsRCR 0.5